The information provided in this section is intended expressly for healthcare professionals in the United States. Click “OK” to enter if you are a US healthcare professional.
NGSa allows for efficient multiplex testing, with the ability to find NTRK gene fusions as well as other key oncogenic drivers.
Select patients for treatment with VITRAKVI® (larotrectinib) based on the presence of an NTRK gene fusion in tumor specimens, as determined by an FDA-approved test. Information on FDA-approved tests is available at http://www.fda.gov/companiondiagnostics